logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Medications for Dermatitis Atopic

    FiltersReset Filters
    53 results

    • adbry

      (tralokinumab-ldrm)
      LEO Pharma Inc.
      Usage: ADBRY is indicated for treating moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and older when topical therapies are insufficient or inappropriate. It can be used alone or in conjunction with topical corticosteroids.

    • cibinqo

      (abrocitinib)
      U.S. Pharmaceuticals
      Usage: CIBINQO is indicated for treating refractory, moderate-to-severe atopic dermatitis in adults and patients aged 12 and older, when the condition is not adequately managed by other systemic therapies or when those treatments are unsuitable. Co-use with other JAK inhibitors or biologics is not recommended.

    • cibinqo

      (abrocitinib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: CIBINQO is indicated for treating adults and pediatric patients aged 12 and older with refractory, moderate-to-severe atopic dermatitis not adequately controlled by other systemic treatments, including biologics, or when those therapies are inadvisable. It is not recommended for use with other JAK inhibitors or immunosuppressants.

    • depo-medrol

      (methylprednisolone acetate)
      Pharmacia & Upjohn Company LLC
      Usage: DEPO-MEDROL is indicated for various conditions, including severe allergic reactions, dermatologic diseases, endocrine and gastrointestinal disorders, hematologic issues, and certain rheumatic diseases. It is also used for cerebral edema, palliative care in neoplastic diseases, and localized therapies in dermatologic conditions via intralesional or intra-articular administration.

    • desonide

      (Desonide)
      Cintex Services, LLC
      Usage: Desonide Gel, 0.05% is indicated for treating mild to moderate atopic dermatitis in patients aged 3 months and older. It should be used for the shortest duration necessary to achieve results, not exceeding 4 consecutive weeks, due to potential HPA axis suppression.

    • dexamethasone

      (Dexamethasone)
      Prasco Laboratories
      Usage: The drug is indicated for severe allergies, dermatologic and endocrine disorders, gastrointestinal and hematologic diseases, neurogenic conditions, neoplastic diseases, and various conditions across respiratory, ophthalmic, renal, and rheumatic diseases. It serves to manage symptoms or provide palliative care in specific cases.

    • dexamethasone

      (dexamethasone)
      Amneal Pharmaceuticals NY LLC
      Usage: This drug is indicated for severe allergic conditions, dermatologic and endocrine disorders, gastrointestinal issues, hematologic disorders, certain cancers, acute nervous system conditions, ocular inflammation, renal diseases, respiratory conditions, and as adjunctive therapy for rheumatic disorders. It addresses various severe and chronic health issues unresponsive to standard treatments.

    • dexamethasone

      (Dexamethasone)
      Rising Pharma Holdings, Inc.
      Usage: This drug is indicated for various conditions, including endocrine and rheumatic disorders, collagen diseases, severe allergic states, ophthalmic and respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, and certain miscellaneous conditions, as well as for diagnostic testing of adrenocortical hyperfunction.

    • dexamethasone sodium phosphate

      (DEXAMETHASONE SODIUM PHOSPHATE)
      Fresenius Kabi USA, LLC
      Usage: The drug is indicated for conditions requiring intravenous, intramuscular, intra-articular, or intralesional administration. It treats endocrine disorders, rheumatic and collagen diseases, severe allergic states, dermatologic issues, various gastrointestinal and respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, and certain nervous system conditions.

    • dexamethasone sodium phosphate

      (Dexamethasone Sodium Phosphate)
      Hikma Pharmaceuticals USA Inc.
      Usage: This drug is indicated for intravenous or intramuscular use in various conditions, including endocrine disorders (e.g., adrenal insufficiency), rheumatic disorders (e.g., rheumatoid arthritis), allergic states, skin diseases, and gastrointestinal issues. It also addresses respiratory, hematologic, neoplastic, and nervous system disorders, with specific applications for intra-articular, soft tissue, and intralesional administration.